Search Within

Dana Elizabeth Rathkopf

Formats
  1. Meeting Abstract (161)
  2. Journal Article (108)
  3. Review (4)
  4. Editorial (3)
  5. Correspondence (1)
Groups
  1. Department of Medicine (277)
  2. Genitourinary Oncology Service (277)
  3. Solid Tumor Oncology Division (277)
  4. Hematologic Malignancies, Division of (70)
  5. GSK Faculty (53)
  6. Department of Pathology and Laboratory Medicine (43)

More Groups

People
  1. Howard Scher (133)
  2. Michael Morris (79)
  3. Susan Slovin (59)
  4. Daniel Danila (45)
  5. Karen Autio (34)
  6. Wassim Abida (31)

More People

Years
  1. 2025 (13)
  2. 2024 (20)
  3. 2023 (19)
  4. 2022 (16)
  5. 2021 (18)
  6. 2020 (12)

More Years

Publications
  1. Journal of Clinical Oncology (122)
  2. Annals of Oncology (27)
  3. European Urology (17)
  4. Clinical Cancer Research (13)
  5. Cancer Research (9)
  6. European Journal of Cancer (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (125)
  2. Oxford University Press (28)
  3. American Association for Cancer Research (26)
  4. Elsevier Science, Inc. (25)
  5. Elsevier Inc. (16)
  6. Nature Publishing Group (9)

More Publishers

Results (277)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of docetaxel and (153)Sm repetitively administered for castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Amodio, A. J.; Gignac, G. A.; Flatts, E.; Slovin, S.; Solit, D.; Rathkopf, D.; Larson, S.; Scher, H. I.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): A phase II trial by the Prostate Cancer Clinical Trials Consortium (NCI 6862)
    Meeting Abstract

    Hussain, M.; Dunn, R.; Rathkopf, D.; Stadler, W.; Wilding, G.; Smith, D. C.; Bradley, D.; Cooney, K. A.; Zweibel, J.; Scher, H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • PCK3145, a novel multitargeted signalling agent for the treatment of castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Dulude, H.; Pancha, C.; Czanny, M.; Curley, T.; Morris, M.; Rathkopf, D.; Schwartz, L.; Heller, G.; Scher, H. I.
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save
  • Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors
    Journal Article

    Fornier, M. N.; Rathkopf, D.; Shah, M.; Patil, S.; O'reilly, E.; Tse, A. N.; Hudis, C.; Lefkowitz, R.; Kelsen, D. P.; Schwartz, G. K.
    Clinical Cancer Research (2007)

    Fulltext@MSK | Save
  • A phase I clinical and pharmacokinetic study of weekly docetaxel followed by flavopiridol: Promising activity in metastatic pancreatic cancer
    Meeting Abstract

    Rathkopf, D.; Fornier, M.; Shah, M. A.; Kortmansky, J.; O'reilly, E.; Winkelmann, J.; Balzano, L.; Kelsen, D. P.; Schwartz, G. K.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors
    Meeting Abstract

    Rathkopf, D.; Fornier, M.; Shah, M.; Kortmansky, J.; O'reilly, E.; King, A.; Winkelmann, J.; Kelsen, D. P.; Olsen, S.; Schwartz, G. K.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Phase I dose-finding study of weekly (W) docetaxel (T) followed by flavopiridol (F) for patients with metastatic solid tumors
    Meeting Abstract

    Fornier, M. N.; Rathkopf, D.; Shah, M.; Hudis, C.; O'reilly, E.; Kortmansky, J.; Winkelmann, J.; Kelsen, D.; Norton, L.; Schwartz, G. K.
    Annals of Oncology (2004)

    Fulltext@MSK | Save